Clinical Trial Update: PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C. [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating PEGASYS (peginterferon alfa-2a) and COPEGUS (ribavirin) after liver transplantation for chronic hepatitis C; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Copegus (ribavirin)
• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hepatitis C, Chronic | Phase 4 | Status: COMPLETED | Results posted: 2011-01-24